1. Home
  2. MITQ vs GRI Comparison

MITQ vs GRI Comparison

Compare MITQ & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Moving iMage Technologies Inc.

MITQ

Moving iMage Technologies Inc.

N/A

Current Price

$0.62

Market Cap

5.4M

ML Signal

N/A

Logo GRI Bio Inc.

GRI

GRI Bio Inc.

N/A

Current Price

$1.85

Market Cap

4.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MITQ
GRI
Founded
N/A
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4M
4.5M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
MITQ
GRI
Price
$0.62
$1.85
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$160.00
AVG Volume (30 Days)
21.2K
385.5K
Earning Date
05-15-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$20,139,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$58.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.42
$0.18
52 Week High
$1.66
$6.70

Technical Indicators

Market Signals
Indicator
MITQ
GRI
Relative Strength Index (RSI) 51.94 56.97
Support Level $0.56 $1.71
Resistance Level $0.57 $2.30
Average True Range (ATR) 0.03 0.15
MACD 0.01 0.02
Stochastic Oscillator 45.72 69.24

Price Performance

Historical Comparison
MITQ
GRI

About MITQ Moving iMage Technologies Inc.

Moving iMage Technologies Inc is engaged in providing designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements. It offers technical, design and consulting services such as custom engineering, systems design, integration and installation and digital technology, as well as software solutions for operations enhancement and theatre management.

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

Share on Social Networks: